Sun, Nov 23, 2014, 2:54 AM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Neurocrine Biosciences Inc. Message Board

hoganedge 6 posts  |  Last Activity: Nov 21, 2014 9:12 AM Member since: May 12, 2008
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • S&P CAPITAL IQ REITERATES STRONG BUY OPINION ON SHARES OF NPS PHARMACEUTICALS

    SNPMarketScopeResearchNotes2014-09-10 10:15:38.000NPSPNPS PHARMACEUTICALS, INC.Jeffrey Loo, CFAS&P CAPITAL IQ REITERATES STRONG BUY OPINION ON SHARES OF NPS PHARMACEUTICALSThe FDA posted briefing materials ahead of its panel meeting on Sept. 12 to review NPSP's BLA for Natpara to treat hypoparathyroidism. The briefing indicated Natpara reduced the need for calcium and vitamin D supplements and the drug was effective with no safety issues. We expect the panel to recommend FDA approval and think Natpara sales could reach blockbuster sales levels in about 7 years and help NPSP achieve long term growth diversification in addition to Gattex, to treat rare disorder short bowel syndrome. Natpara's PDUFA date is October 24. We keep our $42 target price.|US;NPSP|12873|US|216729

    Sentiment: Buy

  • Reply to

    Dreams come true

    by jborg4444 Oct 16, 2014 10:33 AM
    hoganedge hoganedge Oct 16, 2014 1:28 PM Flag

    the rumored price in June was $42, (Shire apparently set up a $5B LOC) that was before the recomendation to approve NATPARA. I doubt an offer could be made prior to PDUFA next week. An approval there, IMO, would require an offer of over $50 since the risk of approval is removed.

    Sentiment: Buy

  • Reply to

    Surprised At Div Increase

    by call_center_tech Nov 20, 2014 12:36 PM
    hoganedge hoganedge Nov 20, 2014 2:53 PM Flag

    In the annual report (i confess, I did not thoroughly read), they have various hedges at approx $90 bbl, declining to the $80 bbl range over the next couple years, so a short term drop in price, should not have a large impact. If prices stay low, we would see a claw back on the distribution rate. Anyone have any additional information as to how much of the production is hedged, did any hedges come with the QRE acquisition?

    Sentiment: Buy

  • Reply to

    Large Insider Sell Isn't Indicative

    by major121sloth Oct 30, 2014 12:53 PM
    hoganedge hoganedge Oct 30, 2014 2:55 PM Flag

    I recall a big deal was made when Nader sold some shares at aroiund $16 prior to the approval of Gattex. I agree insider sales are not a good thing, however, had there been no delay, these sales (if scheduled) would have been after approval. Wholesale selling by insiders liquidating their positions would be a RED flag. These small sales, not so much....thoughts?

    Sentiment: Buy

  • hoganedge hoganedge Oct 28, 2014 3:18 PM Flag

    This was also posted on the company web site: "To date, the FDA has not requested that additional clinical studies be completed prior to the approval of Natpara; however, the company expects a post-approval study commitment."
    I like the last section "post-approval study commitment". Sounds like there has been alot of discussion between NPS and the FDA for them to make a predictive statement like that.

    Sentiment: Buy

  • Reply to

    Surprised At Div Increase

    by call_center_tech Nov 20, 2014 12:36 PM
    hoganedge hoganedge Nov 21, 2014 9:12 AM Flag

    thanks...appreciate the follow up

NBIX
18.95+0.36(+1.94%)Nov 21 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
GameStop Corp.
NYSEFri, Nov 21, 2014 4:04 PM EST
AT&T, Inc.
NYSEFri, Nov 21, 2014 4:00 PM EST